

April 28, 2023

Texas DUR Board

Proposed Retrospective-DUR Interventions

Prepared by Amy Cully, PharmD

Agenda

Recent Interventions

- Hypertension Disease Management
- Management of Psychotropic Drugs in Adults
- Naloxone for High-Risk Patients

Recent Outcome Reports

- Combined Use of Opioids and CNS Depressants DUE 2022
- Management of Psychotropic Drugs in Pediatric Patients 2022

Potential Retro DUR Interventions

- Single Maintenance and Reliever Therapy (SMART) Alternative for Patients with Asthma

Recent RetroDUR Interventions

Intervention	Date Mailed	Provider Letters	Patients
Hypertension Disease Management	3/17/2023	679	773
Management of Psychotropic Drugs in Adults	3/22/2023	129	133
Naloxone in High-Risk Patients	02/17/2023	38	28

Recent Outcome Reports

Intervention	Date Mailed	12-Month State Savings
Combined Use of Opioids and CNS Depressants DUE 2022	4/8/2022	\$6,104.44
Management of Psychotropic Drugs in Pediatric Patients 2022	4/28/2022	\$29,374.70

Recent Outcome Reports:

Combined Use of Opioids and CNS Depressants DUE 2022

Clinical Indicators	Baseline	Oct-2022	% Change
Use of opioid analgesics in combination with benzodiazepines	7	5	-28.6%
Use of opioid analgesics in combination with antipsychotics	2	1	-50.0%
Use of opioid analgesics in combinations with benzodiazepines and antipsychotics	3	2	-33.3%
Use of opioid analgesic in combination with muscle relaxants	1	1	0.0%
Use of opioid analgesics in combination with benzodiazepines and muscle relaxants	2	1	-50.0%
Use of opioid analgesics in combination with sedative hypnotics	0	0	0.0%
Use of opioid analgesics in combination with benzodiazepines, sedative hypnotics or gabapentinoids without naloxone	33	22	-33.3%
Total	48	32	-33.3%

Recent Outcome Reports:

Management of Psychotropic Drugs in Pediatric Patients 2022

Clinical Indicators	Baseline	Nov-2022	% Change
High dose: oral antipsychotics	7	4	-42.9%
Multiple (2 or more) oral antipsychotics or polypharmacy (4 or more psychotropic medications)	51	34	-33.3%
Monitoring of second-generation antipsychotics: glucose or hemoglobin A1c and lipid panel	394	295	-25.1%
Second-generation antipsychotic use with new diabetes and/or lipid lowering medication	2	1	-50.0%
Total	454	334	-26.4%

Potential RetroDUR Intervention:

Single Maintenance and Reliever Therapy (SMART) Alternative for Patients with Asthma

Purpose:

- To provide prescribers with educational tools to better communicate with their patients regarding the treatment of asthma, specifically the newer SMART alternative.

Why Issue was Selected:

- The U.S. Department of Health and Human Services, Centers for Disease Control and Prevention found in 2019 that asthma accounted for 1.5 million emergency department visits.
- Both the Global Initiative for Asthma and National Heart, Lung and Blood Institute recently updated their guidelines on asthma management and recommend the use of single maintenance and reliever therapy (SMART or MART) for some patients with asthma.
- SMART involves using one inhaler consisting of controller and reliever therapy in the form of inhaled corticosteroid (ICS) and formoterol, whereas conventional therapy consists of using two separate inhalers, one as controller and one as reliever.
- SMART is associated with a reduced risk of acute asthma exacerbations, emergency department visits, and hospitalizations when compared to conventional therapy.

Potential RetroDUR Intervention:

Single Maintenance and Reliever Therapy (SMART) Alternative for Patients with Asthma

Setting and Population:

- Providers who have 1 or more patient(s) ≥ 12 years of age with a diagnosis of asthma (COPD and CF patients are eliminated) and have filled 3 or more SABA in the last 180 days.

Type of Intervention:

- Educational letter which includes recommendations from current treatment guidelines regarding SMART.

Outcome Measures:

- Outcome assessment deferred due to anticipated unavailability of claims data post intervention since this will be mailed to providers and not regarding specific patients.

Potential RetroDUR Intervention:

Single Maintenance and Reliever Therapy (SMART) Alternative for Patients with Asthma

Performance Indicators	Number of Letters to Providers
Promote optimization of asthma therapy in patients ≥ 12 years old who may be overutilizing SABA	214

CONDUENT

